ClinicalTrials.gg
RecruitingNCT04955834Updated Sep 21, 2021

A Clinical Study of Insulin Degludec Injection in Subjects With Type 2 Diabetes

A Phase 3 interventional study of Insulin degludec injection and Tresiba® in Type 2 Diabetes, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-09-21.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Jul 2021; still recruiting 5 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
344
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Planned enrollment
38th of 70
344 · median 384
Started
2021
with 3 others
Phase 3
49 of 70
2 open now
Registered
63rd of 70
by date
Lead sponsor
1 of 70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 38th largest by planned enrollment, is one of 4 that started in 2021, is one of 49 in phase 3, and was the 63rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study is a multi-center, randomized, open-label, parallel, positive-controlled registered clinical study,to evaluate the efficacy and safety of insulin degludec injection developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Type 2 diabetes (diagnosed clinically) for at least 6 months.
  2. Aged ≥18 and ≤70 years old, male or female.
  3. Subjects who were treated with a stable dose of oral hypoglycemic agents for more than 3 months before the random visit.
  4. is in the range of 7.5% -11.0 % by local laboratory analysis.
  5. (BMI) ≥18 kg/m2 and ≤40kg/m2.
  6. Patients must give to this study before the trial, and voluntarily sign an informed consent form.
  7. Patients who can communicate well with the investigator and can complete the study in accordance with the research regulations.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed as type 1 diabetes or other types of diabetes.
  2. Patients who have received insulin therapy for more than 7 days within 3 months before screening .
  3. Patients who have received a thiazolidinedione (TZD) or GLP-1 receptor agonist within 3 months before screening.
  4. Patients who are receiving or have received chronic (lasting more than 2 weeks) systemic therapy (excluding topical drugs and inhaled preparations) within 3 months before the random visit.
  5. Patients who are receiving or have received chronic (lasting more than 2 weeks) systemic glucocorticoid therapy (excluding topical drugs and inhaled preparations) within 3 months before the random visit.
  6. Patients with hypoglycemia who have recurring severe events with conscious and/or physical changes within 3 months before screening and need help from others.
  7. Those who have experienced acute metabolic complications (ketoacidosis, lactic acidosis, or hyperosmolar coma, etc.) within 3 months before screening.
  8. Patients with obvious liver and kidney dysfunction.
  9. \<100g/L.
  10. When the virological test during the screening period shows that any of the following is met:

(1) (hepatitis C virus) antibody is positive, and the HCV virus titer test value exceeds the value; (2) (Hepatitis B surface antigen) is positive and the HBV(hepatitis B virus) DNA test value exceeds the upper limit of normal; (3) (human immunodeficiency virus) positive; (4) Active syphilis;

  1. At the time of screening, there are thyroid diseases that have not been controlled with stable doses of drugs within 6 months, and the results of thyroid function tests during the screening period are abnormal and have clinical significance.
  1. Uncontrolled or poorly treated high blood pressure.
  1. Those with decompensated heart failure ( class III and IV), unstable angina, stroke or , myocardial infarction, severe arrhythmia, cardiac surgery or blood vessel reconstruction (including coronary artery bypass grafting or percutaneous coronary intervention) occurred within 6 months before screening.
  1. Those with proliferative retinopathy or macular degeneration (macular edema) that requires urgent treatment during screening.
  1. Once diagnosed as malignant tumor (except for basal cell carcinoma or squamous cell skin cancer).
  1. Patients with severe chronic gastrointestinal diseases (such as active peptic ulcer) and severe infections.
  1. Those who are allergic to any ingredient in insulin deglu injection and Novota®.

18.Those who participated in any other clinical trials within 3 months before screening (excluding those who failed the screening or did not use study drugs for other reasons).

  1. Pregnant women, lactating women, women of childbearing age who do not take appropriate measures during the trial period (sterilization, intrauterine device, oral contraceptives or barrier contraception).
  1. Those who are judged by the investigator to be unsuitable to participate in the trial.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
344 participants (estimated)

Study arms

  • Experimental
    Insulin degludec injection

    Insulin degludec injection subcutaneous administration once daily for 26 weeks in combination with Oral antidiabetic drugs (OADs) used before.

    Drug: Insulin degludec injection

  • Active comparator
    Tresiba®

    Insulin degludec injection(Tresiba®)subcutaneous administration once daily for 26 weeks in combination with Oral antidiabetic drugs (OADs) used before.

    Drug: Tresiba®

Interventions

06

What researchers measure

Primary outcomes

  1. Change value of glycosylated hemoglobin (HbA1c)

    Change value of HbA1c from baseline following 26 weeks of therapy

    Time frame: Baseline and 26 weeks

Secondary outcomes

  1. Percentage of patients achieving HbA1c ≤7% or HbA1c ≤6.5%

    Percentage of patients in each arm achieving HbA1c ≤7% or HbA1c ≤6.5% after 26 weeks of treatment.

    Time frame: Baseline, week 26

  2. Change value of HbA1c

    Change value of HbA1c from baseline following 14 weeks of therapy

    Time frame: Baseline, week 14

  3. Change value of fasting blood glucose

    Change value of fasting blood glucose following 14 and 26 weeks of therapy

    Time frame: Baseline, week 14, week 26

  4. Adverse events (AEs) and serious adverse events (SAEs)

    AEs and SAEs and their incidence during the 26-week treatment period, and then determine the correlation with the drug

    Time frame: Baseline to week 26

  5. Hypoglycemia

    Frequency of severe or symptomatic hypoglycemia during the 26-week treatment period

    Time frame: Baseline to week 26

  6. Immunogenicity

    The occurrence of immunogenicity during the 26-week treatment period by detecting Anti-Drug-Antibody(ADA).

    Time frame: Baseline, week 14, week 26

  7. Abnormal findings

    Abnormal findings during the 26-week treatment period,including abnormal findings of blood routine test,blood biochemical test as well as other abnormal laboratory findings.

    Time frame: Baseline to week 26

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Dec 2025, 53 months after the start.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's planned 53 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2021
First posted
Jul 9, 2021
StartActual
Jul 27, 2021
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Sep 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04955834
Responsible party
Sponsor
First posted
Jul 9, 2021
Start date
Jul 27, 2021
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Sep 21, 2021

Study contacts

Zhiguang Zhou, Doctor
Contact
zhouzg@hotmail.com
0731-85294018
Qifu Li, Doctor
Contact
liqifu@yeah.net
023-89012755

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin degludec

Start the discussion